The Venture Codex

Participated · Series B · Aug 2025

Strand Therapeutics is developing programmable mRNA-based therapeutics that combine self-replicating and circular RNA modalities with genetically programmed logic circuits to enable precise, controlled payload delivery. Its platform is designed to localize and durably express therapeutic payloads, including IL-12, to reprogram the tumor microenvironment and stimulate systemic anti-tumor immunity. The lead program, STX-001, is a self-replicating mRNA encoding IL-12 that is in a Phase 1/2 clinical trial (IND cleared December 2023) and presented early human data at the 2025 ASCO Annual Meeting showing multiple RECIST responses, complete responses, prolonged disease stabilization, and a favorable safety profile. Strand also presented preclinical data for STX-003, a first-in-class systemically administrable, tumor-targeting mRNA therapy programmed to avoid off-target delivery including liver avoidance, at AACR and ASGCT. The company emphasizes a computational design engine and modular platform intended to expand into immuno-oncology, cell therapy, autoimmune diseases, and other indications, and to enable partnerships and licensing opportunities. Strand Therapeutics engineers programmable, long-acting mRNA therapeutics delivered in nanoparticles to control the location, timing, intensity, and duration of protein expression in patients. Its platform programs genetic logic circuits so mRNA senses microRNA signatures and restricts expression to target cells, aiming for improved efficacy and safety versus first-generation mRNA. The company is developing a pipeline of multifunctional mRNA candidates, including a lead programmable mRNA therapy for solid tumor immuno-oncology. Strand plans to advance that lead candidate into Phase 1 clinical trials next year and to further develop a systemic delivery mechanism to target tumor sites and immune cells. The company will expand its biology, bioengineering, bioinformatics, manufacturing, automation, and G&A teams to support clinical and delivery development. Strand is headquartered in Boston and has announced a Series A financing totaling $97 million to support these efforts. Strand Therapeutics develops programmable, long-acting self-replicating mRNA therapeutics designed to enable precise control of location, timing, intensity, and duration of therapeutic activity. Its platform combines self-replicating mRNAs with genetically programmed logic circuits that sense and classify cell-type expression signatures to deliver multi-functional treatments in a single mRNA drug. The company’s initial focus is cancer immunotherapy, with plans to begin clinical trials of its first candidate in 2022 and ambitions to address solid tumors and hematological malignancies. Strand is also developing programmable mRNA for generation of cell therapies intended to be re-doseable and off-the-shelf to expand patient access. The company has a licensing collaboration with BeiGene to develop and commercialize its multi-functional mRNA technology for solid tumor immuno-oncology. Financially, Strand announced an oversubscribed $52M Series A and has raised $66M in total to date. Strand Therapeutics is an early-stage biotechnology company building programmable, “smart” mRNA therapeutics using synthetic biology innovations developed at MIT. The company says it created a bespoke programming language to enable mRNA therapies that can make sophisticated decisions and dynamically respond to their microenvironment. Scientific co-founders include MIT professors Ron Weiss and Darrell J. Irvine; operational co-founders are Jacob Becraft (CEO) and Tasuku Kitada (President). Strand is initially targeting immuno-oncology and plans to extend into other disease indications as the platform matures. The company will use its latest financing to hire at its Cambridge, Massachusetts headquarters, grow its pipeline of engineered gene therapies, and further develop its synthetic biology platform. Strand is a resident company of Johnson & Johnson Innovation, JLABS.

Participated · Series E · Jul 2025

Swift Navigation offers Skylark, a real-time cloud-based precise positioning service that corrects GNSS errors to deliver centimeter-level accuracy for high-volume applications. Skylark is designed for mass-market adoption and operates entirely in the cloud without the need for expensive physical data centers. The service is certified to meet ISO 26262:2018 functional safety standards for road vehicles. Swift reports that Skylark supports over 10 million ADAS-enabled and autonomous vehicles and contributes to global programs for more than 20 automotive OEMs and leading robotics companies. With the new funding, Swift plans to expand adoption across use cases including digital mapping and precision mobile navigation. Timothy Harris is cited as Co-Founder and CEO in the announcement. Swift Navigation offers a comprehensive GNSS platform used across automotive, industrial, and consumer markets. Its products include Skylark, a global wide-area cloud-based GNSS precise positioning service, and Starling, a receiver-agnostic client software positioning engine, along with a variety of Swift and third-party compatible receivers. The platform supports single- and multi-frequency, multi-constellation automotive and commercial-grade GNSS measurement engines and chipsets. Use cases include improved mobile phone positioning (navigation, traffic, augmented reality), continent-wide rail tracking and safety, and enhanced RTK for machine control and guidance in agriculture, construction, and robotics. Customers include automotive OEMs and Tier 1 suppliers, last-mile delivery providers, mobile handset and application companies, and builders of rail, industrial machine control, and IoT platforms. The company intends to use new funding to accelerate growth and expand operations, and to date has raised over $200 million in funding. Swift Navigation builds GNSS and precise positioning technology, including the cloud-based Skylark precise positioning service, the receiver-agnostic Starling software positioning engine, and RTK hardware such as Piksi Multi and Duro devices. Its platform delivers centimeter-accurate, continent-scale positioning across the U.S., Europe, Japan, South Korea, Australia and a growing number of countries. Customers include automotive OEMs, last-mile delivery providers, mobile providers and makers of rail, industrial, micromobility and IoT platforms. The company emphasizes integration with automotive sensor suites and mobile devices to enable lane-level accuracy with privacy and security. Swift plans to use the Series C proceeds to scale customer deployments and continue worldwide expansion. To date the company has raised $97.6 million in funding. Swift Navigation is a San Francisco-based company founded in 2012 by Timothy Harris that develops centimeter-accurate GNSS/GPS technology. Its core products include Piksi Multi, a multi-band, multi-constellation high-precision GNSS receiver with seconds-level convergence, and Duro, a ruggedized version for harsh outdoor deployments. The company serves over 2,000 customers across autonomous vehicles, precision agriculture, UAVs, robotics, maritime, transportation/logistics and outdoor industrial applications. In June 2017 it raised $34M in a Series B, bringing total funding to $47.6M. Swift plans to use the funds to scale customer deployments, grow its team, and invest in core engineering and R&D. It also intends to introduce additional next-generation products in 2017. Swift Navigation develops accurate Real Time Kinematics (RTK) GPS positioning technology for applications including unmanned aerial vehicles, precision agriculture, self-driving cars, robotics and surveying. Led by CEO Tim Harris, the company has sold its first product, Piksi™, to over 1,200 customers. Swift is planning to introduce two next-generation products in 2016. Financially, the company has raised a total of $13.6M to date. The firm intends to use new funding to scale and grow its team and to invest in core engineering and R&D.

Participated · Series C · Feb 2022

Beyond Identity offers an invisible, un‑phishable MFA platform that cryptographically binds a user’s identity to their device using public/private key technology and X.509 certificates, eliminating passwords from authentication and account recovery. Its core architecture, modern authenticator, and advanced policy engine ensure only authorized users and authorized devices are granted access and that devices comply with security policies before and after authentication. The company launched Secure Customers and Secure DevOps in 2021 and added dozens of integrations with identity and cybersecurity products across MDM, EDR, SIEM, and code repositories. Beyond Identity reported ARR growth of 330% from 2020 to 2021, a 640% increase in its customer roster, and has more than 180 employees including over 100 developers. The company says the new funding will be used to expand research and development and extend its footprint and resources into Asia‑Pacific and Latin America. Beyond Identity provides a cloud-native, standards-based passwordless identity platform that replaces passwords with X.509-based certificates and enables continuous, risk-based authentication. The company’s patents-pending approach creates an extended Chain of Trust™ intended to improve security and deliver a frictionless login experience. Beyond Identity serves customers with workforces ranging from under a hundred to hundreds of thousands, and works with businesses deploying its platform to tens of millions of end users. Launched in April 2020 by Jim Clark and Thomas (TJ) Jermoluk, the company emphasizes advanced, standards-based architecture. The firm intends to use new capital to accelerate product innovation and to build a global presence through expanded distribution channels, OEM partners, and international sales and support. The company is based in New York City. Beyond Identity provides a cloud-native passwordless identity management platform that leverages existing secure communications infrastructure and crypto standards to extend the trust boundary to include users and their devices. Its approach removes the need for shared-secret, password-based authentication and reduces dependence on compensating controls. The company initially targets businesses seeking stronger workforce and customer authentication and elimination of central password database risk. It also plans to target individual consumers who do not want to use passwords or third‑party “login with” solutions. Beyond Identity was co-founded by Jim Clark and Tom Jermoluk. The company plans to use the new funding to expand operations and broaden its business reach.